Departments of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA.
J Biol Chem. 2012 Jun 15;287(25):20975-85. doi: 10.1074/jbc.M112.341479. Epub 2012 Apr 27.
Phospho-telokin is a target of elevated cyclic nucleotide concentrations that lead to relaxation of gastrointestinal and some vascular smooth muscles (SM). Here, we demonstrate that in telokin-null SM, both Ca(2+)-activated contraction and Ca(2+) sensitization of force induced by a GST-MYPT1(654-880) fragment inhibiting myosin light chain phosphatase were antagonized by the addition of recombinant S13D telokin, without changing the inhibitory phosphorylation status of endogenous MYPT1 (the regulatory subunit of myosin light chain phosphatase) at Thr-696/Thr-853 or activity of Rho kinase. Cyclic nucleotide-induced relaxation of force in telokin-null ileum muscle was reduced but not correlated with a change in MYPT1 phosphorylation. The 40% inhibited activity of phosphorylated MYPT1 in telokin-null ileum homogenates was restored to nonphosphorylated MYPT1 levels by addition of S13D telokin. Using the GST-MYPT1 fragment as a ligand and SM homogenates from WT and telokin KO mice as a source of endogenous proteins, we found that only in the presence of endogenous telokin, thiophospho-GST-MYPT1 co-precipitated with phospho-20-kDa myosin regulatory light chain 20 and PP1. Surface plasmon resonance studies showed that S13D telokin bound to full-length phospho-MYPT1. Results of a protein ligation assay also supported interaction of endogenous phosphorylated MYPT1 with telokin in SM cells. We conclude that the mechanism of action of phospho-telokin is not through modulation of the MYPT1 phosphorylation status but rather it contributes to cyclic nucleotide-induced relaxation of SM by interacting with and activating the inhibited full-length phospho-MYPT1/PP1 through facilitating its binding to phosphomyosin and thus accelerating 20-kDa myosin regulatory light chain dephosphorylation.
磷酸化telokin 是一种靶标,可被升高的环核苷酸浓度所激活,导致胃肠道和一些血管平滑肌(SM)的松弛。在这里,我们证明在 telokin 缺失的 SM 中,添加重组 S13D telokin 拮抗 GST-MYPT1(654-880)片段抑制肌球蛋白轻链磷酸酶所诱导的 Ca(2+)-激活收缩和力的 Ca(2+)敏感化,而不会改变内源性 MYPT1(肌球蛋白轻链磷酸酶的调节亚基)在 Thr-696/Thr-853 的抑制性磷酸化状态或 Rho 激酶的活性。在 telokin 缺失的回肠肌肉中,环核苷酸诱导的力松弛减少,但与 MYPT1 磷酸化的变化无关。在 telokin 缺失的回肠匀浆中,添加 S13D telokin 将磷酸化 MYPT1 的 40%抑制活性恢复到非磷酸化 MYPT1 水平。使用 GST-MYPT1 片段作为配体,并用 WT 和 telokin KO 小鼠的 SM 匀浆作为内源性蛋白的来源,我们发现仅在存在内源性 telokin 的情况下,硫代磷酸化-GST-MYPT1 与磷酸化 20-kDa 肌球蛋白调节轻链 20 和 PP1 共沉淀。表面等离子体共振研究表明 S13D telokin 与全长磷酸化 MYPT1 结合。蛋白质连接测定的结果也支持内源性磷酸化 MYPT1 与 SM 细胞中的 telokin 相互作用。我们得出结论,磷酸化 telokin 的作用机制不是通过调节 MYPT1 的磷酸化状态,而是通过与和激活被抑制的全长磷酸化 MYPT1/PP1 相互作用,通过促进其与磷酸化肌球蛋白的结合,从而加速 20-kDa 肌球蛋白调节轻链的去磷酸化,从而促进 SM 中环核苷酸诱导的松弛。